Dietary lipids and carbohydrates in the gastrointestinal tract

Dietary lipids and carbohydrates in the gastrointestinal tract represent the primary macronutrient sources of energy for the human body, undergoing complex mechanical and chemical digestion before absorption (StatPearls: Physiology, Digestion and Absorption, 2023). Lipids, primarily in the form of triglycerides, are emulsified by bile salts and hydrolyzed by pancreatic lipase into fatty acids and monoglycerides, while complex carbohydrates are broken down into simple monosaccharides by enzymes such as amylase and alpha-glucosidase (PubMed: Lipid Digestion and Absorption, 2021; NIH: Carbohydrate Metabolism, 2022). Dysregulation of these digestive and absorptive processes is a central factor in the development of metabolic diseases, including obesity, type 2 diabetes, and hyperlipidemia (Lancet: Global Burden of Metabolic Risk Factors, 2020). Pharmacological interventions often target the enzymes responsible for these processes, such as using orlistat to inhibit lipase or acarbose to inhibit alpha-glucosidase, thereby reducing caloric intake and blunting postprandial glucose spikes (Mayo Clinic: Diabetes Medications, 2023). While effective for metabolic management, these therapies are frequently associated with gastrointestinal side effects, such as steatorrhea and flatulence, caused by the fermentation or passage of undigested nutrients in the large intestine (FDA: Xenical Prescribing Information). This entry is classified as incorrect as a single target because it describes a broad physiological process and a group of substrates rather than a specific molecular receptor or enzyme.

Other names

Macronutrient digestion and absorptionIntestinal nutrient processingGastrointestinal lipid and carbohydrate metabolism

Drugs targeting these processes typically act by inhibiting specific digestive enzymes, such as pancreatic lipase for lipids or alpha-glucosidase for carbohydrates, to prevent the breakdown of complex macronutrients into absorbable units (StatPearls: Physiology, Digestion and Absorption, 2023). Other agents, like ezetimibe, specifically inhibit transport proteins like NPC1L1 to reduce the absorption of dietary cholesterol (PubMed: NPC1L1 and Cholesterol Transport, 2021).